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Abstract
JMJD2D, also known as KDM4D, is a histone demethylase that removes methyl moieties from lysine 9 on histone 3 and from
lysine 26 on histone 1.4. Here, we demonstrate that JMJD2D forms a complex with the p53 tumor suppressor in vivo and
interacts with the DNA binding domain of p53 in vitro. A luciferase reporter plasmid driven by the promoter of p21, a cell
cycle inhibitor and prominent target gene of p53, was synergistically activated by p53 and JMJD2D, which was dependent
on JMJD2D catalytic activity. Likewise, overexpression of JMJD2D induced p21 expression in U2OS osteosarcoma cells in the
absence and presence of adriamycin, an agent that induces DNA damage. Furthermore, downregulation of JMJD2D
inhibited cell proliferation in wild-type and even more so in p53
2/2 HCT116 colon cancer cells, suggesting that JMJD2D is
a pro-proliferative molecule. JMJD2D depletion also induced more strongly apoptosis in p53
2/2 compared to wild-type
HCT116 cells. Collectively, our results demonstrate that JMJD2D can stimulate cell proliferation and survival, suggesting that
its inhibition may be helpful in the fight against cancer. Furthermore, our data imply that activation of p53 may represent
a mechanism by which the pro-oncogenic functions of JMJD2D become dampened.
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Introduction
The JMJD (Jumonji C domain) family comprises ,30 proteins
in mammals that are characterized by the Jumonji C (JmjC)
domain. In many, but not all JMJD proteins, this JmjC domain
has catalytic activity and mediates the demethylation of histone
lysine residues [1,2]. Thus, JMJD proteins are involved in the
dynamic modulation of histone posttranslational modification that
governs virtually all processes within the cell, including regulation
of gene transcription, epigenetic silencing, heterochromatin
formation, genomic imprinting and DNA repair. Accordingly,
dysregulation of JMJD protein activity can lead to diseases such as
cancer [3,4].
One subfamily of JMJD proteins consists of JMJD2A–D in
humans [5]. Whereas JMJD2A–C are ,120 kDa proteins and
possess double PHD and Tudor domains, which are implicated in
binding to methylated histones [6], JMJD2D is only half the size
and lacks PHD and Tudor domains. In contrast to JMJD2A–C,
the whole open reading frame of JMJD2D is encoded in one exon,
hinting that the JMJD2D gene evolved from a reverse-transcribed
JMJD2 mRNA. In addition, two other genomic sequences
(JMJD2E and F) are similar to JMJD2D, but it remains unclear
whether these DNA sequences are expressed into respective
proteins [5]. Furthermore, whereas JMJD2A–C demethylate tri-
and dimethylated histone 3 (H3) on both K9 and K36 [7–10],
JMJD2D is unable to demethylate H3K36. However, JMJD2D
demethylates not only tri- and dimethylated H3K9, but also, albeit
with reduced efficiency, monomethylated H3K9 [11,12].
Hitherto, little is known about the physiological role of
JMJD2D, also called KDM4D for lysine demethylase 4D. The
first function of JMJD2D revealed was in androgen signaling [13].
JMJD2D was reported to interact with the ligand binding domain
of the androgen receptor and thereby activate androgen-de-
pendent gene transcription. This ability of JMJD2D to stimulate
the androgen receptor was dependent on its catalytic activity,
which is consistent with the fact that especially trimethylated
H3K9 is a repressive chromatin mark [14]. Moreover, JMJD2D is
not an essential protein, since respective knock-out mice are viable
and display no obvious phenotype. However, consistent with
JMJD2D mRNA being most highly expressed in testes, H3K9
methylation in spermatids was altered in JMJD2D
2/2 mice:
trimethylated H3K9 accumulated in round spermatids and di-/
monomethylated H3K9 in elongated spermatids that have no
detectable trimethylated H3K9 [15], corroborating that JMJD2D
is an effective in vivo demethylase of H3K9. Despite these changes
of H3K9 methylation in spermatids, JMJD2D
2/2 male mice
surprisingly showed no decline in fertility [15].
Lysine methylation is not restricted to histones, but appears to
occur on many proteins including estrogen receptor, androgen
receptor, the RelA subunit of the NF-kappaB transcription factor,
the coactivator PCAF and the basal transcription factor TAF10
[16–21]. In particular, multiple lysine methylation sites were
identified in the tumor suppressor p53 that activate or repress its
function depending on which lysine is modified and what the
modification status is (mono- or dimethylated) [22–25]. While
respective methyltransferases were uncovered that target p53, it
remains largely unknown which enzymes are capable of
demethylating p53. We wondered if JMJD2D might demethylate
p53 and thus started to analyze the relationship between JMJD2D
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34618and p53. In addition, we explored herein whether JMJD2D affects
the physiology of human HCT116 colon cancer cells.
Materials and Methods
Coimmunoprecipitation Assay
Human embryonal kidney HEK293T cells (American Type
Culture Collection CRL-11268) were seeded into 6-cm dishes
coated with poly-L-lysine and grown in DMEM media supple-
mented with 10% fetal bovine serum, 100 u/ml penicillin and
100 mg/ml streptomycin at 37uC in a humidified atmosphere
containing 10% CO2 [26]. At 25% confluency, cells were
transiently transfected by the calcium phosphate coprecipitation
method [27] with 5.5 mg pBluescript KS
+ (Stratagene), 1.5 mg
empty pcDNA3 vector or pcDNA3-p53, and 2 mg empty pEV3S
vector or Flag-tagged expression plasmid for JMJD2D, HSPBAP1
[11], SMCX [28], JHDM1A or JMJD6 [29]. The DNA-calcium
phosphate coprecipitate was allowed to form and transfect cells for
12 h in an atmosphere containing 3% CO2. Then, cells were
washed twice with 2 ml phosphate-buffered saline and grown
thereafter for 36 h in an atmosphere containing 10% CO2. After
that, cells were lysed in 50 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 50 mM NaF, 0.25 mM Na3VO4, 0.2 mM DTT, 0.5% NP-
40, 2 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mg/ml pepstatin A,
1 mM phenylmethylsulfonyl fluoride and immunoprecipitations
performed with anti-Flag M2 (Sigma F3165) or anti-p53 DO-1
(Santa Cruz Biotechnology sc-126) monoclonal antibodies essen-
tially as described before [30]. Similarly, endogenous JMJD2D in
HCT116 cells (American Type Culture Collection CCL-247) was
immunoprecipitated with anti-JMJD2D antibodies (Aviva Systems
Biology ARP35946). Precipitates were then subjected to SDS
polyacrylamide gel electrophoresis followed by Western blotting
and coprecipitated proteins revealed utilizing M2 or DO-1
antibodies employing enhanced chemiluminescence [31].
GST Pull-downs
Glutathione S-transferase (GST) fusion proteins were produced
in Escherichia coli and purified according to standard procedures
[32]. Cell extract containing Flag-tagged JMJD2D protein was
prepared from transiently transfected HEK293T cells as described
before [33]. This cell extract was then incubated with GST fusion
proteins bound to glutathione agarose beads in 20 mM HEPES,
50 mM NaCl, 1 mM DTT, 0.01% Tween-20, 0.5 mM phenyl-
methylsulfonyl fluoride for 3 h at 4uC. After three washes in the
same buffer [34], any Flag-tagged JMJD2D bound to GST fusion
proteins was revealed by Western blotting utilizing M2 mono-
clonal antibodies.
Luciferase Assay
HEK293T cells were grown in poly-L-lysine-treated 12-wells as
described above. When reaching 25% confluency, cells were
transiently transfected by the calcium phosphate coprecipitation
method [35] with 200 ng of luciferase reporter constructs driven
by the human p21 promoter (22324/+100), the human matrix
metalloproteinase-1 (MMP-1) promoter [36], or the cytomegalo-
virus (CMV) promoter/enhancer [37]. In addition, 50 ng empty
pcDNA3 vector or pcDNA3-p53, 300 ng empty pEV3S vector or
Flag-JMJD2D, and 1.8 mg pBluescript KS
+ (Stratagene) were
cotransfected. After 10 h, cells were washed twice with 1 ml
phosphate-buffered saline and then incubated for another 36 h in
media [38]. Thereafter, cells were washed once with 1 ml
phosphate-buffered saline and lysed in 0.3 ml of 25 mM Tris-
HCl (pH 7.8), 2 mM EDTA, 2 mM DTT, 1% Triton X-100 and
10% glycerol [39]. Luciferase activity was then determined in
a luminometer [40].
Chromatin Immunoprecipitation Assay
This assay was essentially performed as described before [41]
with JMJD2D (Aviva Systems Biology ARP35946), p53 DO-1
(Santa Cruz Biotechnology sc-126) and H3K9me3 (Upstate 07–
442) antibodies. As a control, the cytoplasmic Rcl protein [42] was
immunoprecipitated. To amplify a p21 promoter fragment, the
primer pair 59-GTGGCTCTGATTGGCTTTCTG-39 and 59-
CCAGCCCTGTCGCAAGGATC-39 was employed [43] and
amplified DNA resolved and visualized on an ethidium bromide-
stained agarose gel [44].
Generation of Stably Transfected U2OS Cells
Flag-JMJD2D, Flag-JMJD2D-H192A or pEV3S were em-
ployed to transfect U2OS cells (American Type Culture Collection
HTB-96) by the calcium phosphate coprecipitation method as
described above. Two days after transfection, cells were split at
a ratio of 1:100, 1:200, 1:400 and 1:800 and grown until visible
colonies were formed. Twenty colonies were picked, expanded
and analyzed by Western blotting for the expression of Flag-tagged
proteins. One cell line each for the transfected plasmids was then
selected for further analysis. These stably transfected U2OS cells
were treated with DMSO or 1 mM adriamycin (stock solution of
4 mM dissolved in DMSO) for 24 h, cell extracts prepared by
boiling in Laemmli buffer [45] and analyzed by Western blotting
[46] employing antibodies against JMJD2D (Aviva Systems
Biology ARP35946), p21 (Santa Cruz Biotechnology sc-756),
Figure 1. Binding of JMJD2D to p53. (A) Flag-tagged JMJD2D or
HSPBAP1 were coexpressed with p53 in HEK293T cells. After anti-p53
immunoprecipitation (IP), coprecipitated proteins were revealed by
anti-Flag immunoblotting (top panel). The bottom two panels show
input levels of Flag-tagged proteins or p53. IgH, immunoglobulin heavy
chain. (B) Indicated Flag-tagged JMJD proteins were coexpressed with
p53 in HEK293T cells. After anti-Flag immunoprecipitation, coprecipi-
tated p53 was detected by anti-p53 Western blotting (top panel). The
middle and bottom panels show p53 and Flag-JMJD protein input
levels, respectively. (C) HCT116 cell extracts were challenged with no,
control or anti-JMJD2D antibodies and coprecipitated p53 detected by
immunoblotting (top panel). The bottom panel shows that respective
JMJD2D input levels were equal.
doi:10.1371/journal.pone.0034618.g001
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(Upstate 07–441), H3K9me1 (Upstate 07–450) or histone H3
(Santa Cruz Biotechnology sc-10809).
RT-PCR
Stably transfected U2OS cells were treated with DMSO or
1 mM adriamycin (stock solution of 4 mM dissolved in DMSO) for
18 h and RNA then prepared utilizing Trizol (Invitrogen)
according to the manufacturer’s instructions. RT-PCR was
performed employing the Access RT-PCR kit (Promega) with
p21-RT-for-2 (59-GTTTCTGCGGCAGGCGCCATG-39) and
p21-RT-rev-2 (59-GGGCGGATTAGGGCTTCC-39) primers
under the following conditions: 48uC for 45 min, 95uC for
2 min, 20 or 25 cycles of 94uC for 30 s, 58uC for 30 s, 72uC for
30 s, and a final extension step at 72uC for 2 min. DNA was
electrophoresed on an agarose gel and visualized by ethidium
bromide staining. The expected length of the p21 cDNA was
520 bp. A 226 bp control GAPDH (glyceraldehyde 3-phosphate
dehydrogenase) cDNA was amplified as described previously [47].
Retroviral Infection
The retroviral expression vector pSIREN-RetroQ (Clontech)
was employed to express shRNAs. The following sequences within
human JMJD2D were targeted: GCCAGAGAGACCTATGATA
(#1) and ACCACGTTTGCTTGGCATA (#3). To generate
respective retrovirus, HEK293T cells were cotransfected with the
shRNA vector and necessary packaging plasmids [48]. Super-
natants containing retrovirus were collected 48 h and 72 h after
transfection, passed through a 0.45 mm filter, and concentrated by
precipitation with poly(ethylene glycol)-8000. Then, cells were
infected three times (every 12 h) with retrovirus [49]. Sub-
sequently, cells were selected for two days in 1 mg/ml puromycin,
as the pSIREN-RetroQ vector encodes the respective antibiotica
resistance gene. Then, cells were treated without or with 1 mM
adriamycin for indicated times and JMJD2D and actin protein
expression determined as described above.
Cell Proliferation Assay
50,000 retrovirally infected cells were plated into 6-cm dishes.
Cells were then treated with 1 mM adriamycin or DMSO as
a control for 72 h, harvested, stained with trypan blue and live
cells totaled with the help of a Countess cell counter (Invitrogen)
according to the manufacturer’s recommendations. Experiments
were performed in triplicate and averages with standard error are
shown. Statistical significance was determined with an unpaired,
two-tailed t-test.
Flow Cytometry
Retrovirally infected cells were grown in 6-cm dishes for 72 h.
Then, cells were harvested, washed in phosphate-buffered saline,
fixed in 63% ethanol for 12 h at 4uC, and incubated with 40 mg/
ml propidium iodide and 50 mg/ml RNase A for 30 min at 37uC
[50]. After that, the proportion of sub-G1 cells was determined by
sampling 20,000 events with a FACSCalibur flow cytometer
utilizing Cell Quest software (BD Biosciences). Triplicate experi-
ments were performed and statistical significance determined with
an unpaired, two-tailed t-test.
Results
Interaction between JMJD2D and p53
Previously, it was reported that the human tumor suppressor
p53 can be mono-/dimethylated on K370, K372 and K382, yet
only one protein, lysine-specific demethylase 1, has been identified
that is able to demethylate p53 by targeting K370 [22–25]. We
speculated that JMJD2D might demethylate p53 and thus
analyzed the ability of JMJD2D to demethylate p53 peptides
encompassing di- or monomethylated K370, K372 or K382 in
vitro. However, we found that JMJD2D was unable to demethylate
any of these peptides (not shown). At the same time, we reasoned
that a potential demethylase might interact with its substrate and
therefore analyzed in parallel whether JMJD2D would form
a complex with p53 in vivo. To this end, we coexpressed Flag-
tagged JMJD2D and p53 in HEK293T cells, immunoprecipitated
with anti-p53 antibodies and then probed for the presence of
JMJD2D by anti-Flag Western blotting. Indeed, JMJD2D was
revealed when p53 was coexpressed (Fig. 1A, top panel). In
contrast, another JMJD protein, HSPBAP1, did not coimmuno-
precipitate with p53 (Fig. 1A, top panel), although comparable
levels of Flag-tagged HSPBAP1 and JMJD2D were expressed
(Fig. 1A, middle panel), indicating that our immunoprecipitation
assay was specific. To confirm this complex formation between
p53 and JMJD2D, we performed also reverse-order coimmuno-
precipitation assays. Again, we observed that p53 and JMJD2D
formed a complex in vivo and once more this was specific, since
three other JMJD proteins (SMCX, JHDM1A, JMJD6) did not
coimmunoprecipitate p53 (Fig. 1B). Finally, we assessed whether
endogenous p53 and JMJD2D also form complexes. For this, we
employed human HCT116 colon cancer cells that endogenously
express both p53 and JMJD2D. Immunoprecipitation with anti-
JMJD2D antibodies, but not with control or no antibodies, pulled
down p53 (Fig. 1C) demonstrating that endogenous JMJD2D and
p53 interact in vivo.
Next, we analyzed which protein domains might be responsible
for the JMJD2D-p53 interaction. In coimmunoprecipitation
experiments, the N-terminal 354 amino acids of JMJD2D were
unable to pull down p53, but the C-terminal amino acids 241–523
did (Fig. 2A). Thus, the catalytic JmjC domain stretching from
amino acid 146–312 does not mediate this interaction. This
provides an explanation why SMCX, JHDM1A or JMJD6 and
possibly many more JMJD proteins do not interact with p53,
because their common denominator, the JmjC domain, is not
sufficient to facilitate this interaction. Conversely, we employed
Figure 2. Mapping of interaction domains. (A) Indicated Flag-
tagged amino acids of JMJD2D were coexpressed with p53 in HEK293T
cells and complex formation assessed in coimmunoprecipitation assays
as in Fig. 1B. A sketch of human JMJD2D highlighting its JmjC domain is
presented at the bottom. (B) Comparable amounts of GST or indicated
GST-p53 fusion proteins were bound to glutathione agarose. After
incubation with Flag-tagged JMJD2D, bound JMJD2D was revealed by
anti-Flag Western blotting. The location of the DNA binding domain
within p53 is indicated in the sketch at the bottom.
doi:10.1371/journal.pone.0034618.g002
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capable of binding to JMJD2D. As shown in Fig. 2B, full-length
p53 as well as its central DNA binding domain interacted in vitro
with JMJD2D, whereas the N- and C-terminus of p53 did not.
Stimulation of p53 by JMJD2D
The physical interaction with p53 suggested that JMJD2D
modulates the transcriptional activity of p53. One prominent p53
target gene is the p21 cell cycle inhibitor [51]. Thus, we employed
a p21 luciferase reporter gene to analyze the impact of JMJD2D
on p53-dependent transcription. As expected, expression of p53
alone resulted in increased p21 promoter activity in HEK293T
cells (Fig. 3A). Expression of JMJD2D slightly enhanced luciferase
activity, whereas the combination of p53 and JMJD2D displayed
a synergistic activation of the p21 promoter. Notably, mutating the
catalytic center of JMJD2D by replacing the crucial histidine
residue 192 with alanine abrogated this synergy (see H192A
mutant in Fig. 3A). Furthermore, JMJD2D’s ability to coactivate
was specific, since the CMV promoter was unaffected by p53 and/
or JMJD2D overexpression and the MMP-1 promoter was
repressed by p53, whereas JMJD2D had no effect (Fig. 3B). We
conclude that JMJD2D is capable of stimulating p53-dependent
transcription and that its catalytic activity is required to do so.
To further confirm this notion, we studied binding of JMJD2D
to the endogenous p21 promoter in HCT116 cells by chromatin
immunoprecipitation assays. Moreover, we treated these cells with
the DNA damaging agent adriamycin, which is known to induce
p53 activity and hence p21 expression. As expected, adriamycin
treatment enhanced binding of p53 to the p21 promoter (Fig. 3C).
Likewise, JMJD2D binding increased upon adriamycin treatment,
and simultaneously H3K9 trimethylation became reduced. These
data suggest that JMJD2D binds to the p21 gene promoter
together with p53 and possibly contributes to p21 gene activation
by reducing levels of trimethylated H3K9.
Next, we established human U2OS osteosarcoma cells that
stably express either wild-type JMJD2D or its catalytic H192A
mutant. Whereas we did not detect any significant amounts of
endogenous JMJD2D in wild-type U2OS cells, strong levels of
JMJD2D were observed in stably transfected U2OS cells (Fig. 4A).
Moreover, both in control and in adriamycin-treated cells,
JMJD2D expression led to enhanced p21 protein levels (Fig. 4A),
further substantiating that JMJD2D is a coactivator of p53. In
addition, similar as reported before for HEK293T cells [11], we
observed that JMJD2D overexpression in U2OS cells led to
globally reduced levels of tri- and dimethylated H3K9, whereas
levels of monomethylated H3K9 were enhanced. In contrast, the
H192A mutant did not change global H3K9 methylation levels
and also did not raise p21 proteins levels, again suggesting that
catalytic activity of JMJD2D is required for its ability to coactivate
p53 (Fig. 4A). However, there is the caveat that we were unable to
Figure 3. Activation of the p21 promoter by JMJD2D in HEK293T cells. (A) Activity of a p21 luciferase reporter construct upon
cotransfection of control vector pEV3S or wild-type or H192A JMJD2D is depicted. As indicated, empty vector pcDNA3 or pcDNA3-p53 was also
transfected. (B) Analogous, response of a CMV or MMP-1 luciferase reporter construct to cotransfection of p53 and/or JMJD2D. (C) Chromatin
immunoprecipitation assay in HCT116 cells treated without and with adriamycin.
doi:10.1371/journal.pone.0034618.g003
Figure 4. Stimulation of p21 expression by JMJD2D in U2OS
cells. (A) Wild-type or H192A JMJD2D or empty vector pEV3S were
stably transfected into U2OS cells. Expression of indicated proteins was
assessed by Western blotting in cells treated for 24 h with 1 mM
adriamycin or DMSO as a control. (B) RNA was isolated from stably
transfected U2OS cells and RT-PCR analyses were performed. Shown is
the amplification of p21 cDNA and, as a control, GAPDH cDNA.
doi:10.1371/journal.pone.0034618.g004
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as wild-type JMJD2D; this may suggest that the catalytic mutant
exerts toxic effects in U2OS cells.
To demonstrate that JMJD2D indeed affects transcription of the
endogenous p21 gene, we also isolated RNA from our stably
transfected U2OS cells. RT-PCR experiments were then
performed, which showed that p21 mRNA levels were strongly
enhanced by JMJD2D, whereas JMJD2D-H192A overexpression
had very little effect (Fig. 4B). This was observed both in the
presence and absence of adriamycin. Altogether, our data indicate
that JMJD2D stimulates the transcription of the p53 target gene,
p21.
Impact of JMJD2D on Cell Proliferation and Survival
Next, we attempted to study the physiological role of JMJD2D
and chose human HCT116 colon cancer cells for analysis, because
matching wild-type and p53
2/2 HCT116 cells are available [52]
and because endogenous JMJD2D was readily detectable. First, we
generated two shRNAs targeting JMJD2D, both of which
significantly reduced JMJD2D levels in HCT116 cells (Fig. 5A).
Then we assessed how downregulation of JMJD2D would affect
proliferation. In comparison to HCT116 cells infected with
a retrovirus expressing a control shRNA, virus delivering
JMJD2D#1 or JMJD2D#3 shRNA caused a significant decrease
in cell number (Fig. 5B). Please note that different cell numbers do
not necessarily equate with different rates of proliferation, since
this may (partly) be due to altered apoptosis levels. However, we
only observed a ,3% increase in apoptotic cells when down-
regulating JMJD2D (see below and Fig. 6A), which is unlikely to
account for the ,30% decrease of cell number in JMJD2D-
depleted cells; thus, we believe that the main cause of decreased
cell number upon JMJD2D depletion is reduced cell proliferation.
Figure 5. JMJD2D depletion results in reduced cell proliferation. (A) HCT116 cells expressing control or JMJD2D shRNA were treated with
1 mM adriamycin or with DMSO as a control for 24 h. Downregulation of JMJD2D was assessed by Western blotting; immunoblotting for actin served
as a loading control. (B) Wild-type or p53
2/2 HCT116 cells were challenged with control or JMJD2D shRNA (#1o r#3) and then treated without or
with 1 mM adriamycin for 72 h. The number of cells were counted and presented as percent of the control shRNA for each wild-type and p53
2/2
HCT116 cells. Statistical significance of differences between various experimental conditions is indicated in the graph.
doi:10.1371/journal.pone.0034618.g005
Figure 6. JMJD2D protects from apoptosis. (A) The level of sub-G1 HCT116 cells was determined in cells that expressed control shRNA or
JMJD2D shRNA#3. Cells were treated for 72 h with 1 mM adriamycin or DMSO as indicated. (B) The same in case of p53
2/2 HCT116 cells. (C) Model of
JMJD2D action.
doi:10.1371/journal.pone.0034618.g006
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in a reduction of cell number and JMJD2D depletion further
reduced cell numbers. Next, we assessed the same in p53
2/2
HCT116 cells. Again, we observed that JMJD2D depletion led to
reduced cell numbers both in the absence and presence of
adriamycin; interestingly, it appears that JMJD2D depletion had
a greater effect in p53
2/2 compared to wild-type HCT116 cells
(Fig. 5B).
In addition, we assayed the impact of JMJD2D depletion on cell
death, which was monitored by determining cells that had a sub-
G1 DNA content. In wild-type HCT116 cells, JMJD2D knock-
down resulted in a ,2-fold increase of apoptotic cells (3.3% to
6.5%; Fig. 6A), whereas apoptosis was more pronouncedly
enhanced upon JMJD2D depletion in p53
2/2 HCT116 cells
(5.5% to 20.0%; Fig. 6B). Similarly, JMJD2D knock-down resulted
in more apoptosis in adriamycin-treated p53
2/2 compared to
wild-type HCT116 cells (29.3% versus 19.5%; Fig. 6A and 6B).
Collectively, these data indicate that JMJD2D promotes cell
survival in both p53
+/+ and p53
2/2 HCT116 cells.
Discussion
Here, we have provided evidence that the histone demethylase
JMJD2D is a coactivator of p53. JMJD2D can interact with the
DNA binding domain of p53 and synergize with p53 to induce
expression of p21, a cell cycle inhibitor and prominent p53 target
gene [51]. Thus, it is likely that JMJD2D will cooperate with p53
at many more of its target gene promoters, but comprehensive
genome-wide studies are needed to corroborate this experimen-
tally. One mechanism by which JMJD2D may stimulate p53-
dependent transcription is by especially demethylating trimethy-
lated H3K9, a mark of repressed genes [14], and accordingly we
observed that catalytic activity of JMJD2D was required for its
ability to stimulate the p21 gene promoter. In addition to targeting
H3K9, JMJD2D was recently shown to demethylate H1.4K26
[12,53]. Moreover, histone H1.4 is enriched in heterochromatin,
confers transcriptional repression and recruits heterochromatin
binding protein 1 when methylated [54–56]. Thus, JMJD2D may
also induce p53 target genes by removing repressive methylation
marks from H1.4K26. Interestingly, JMJD2A has recently been
shown to act as a p53 corepressor [43], indicating that JMJD2D is
distinct from JMJD2A and can perform an opposite function in
transcriptional regulation.
Downregulation of JMJD2D in HCT116 colon cancer cells
revealed that JMJD2D is a pro-proliferative molecule, showing for
the first time a physiological role for this demethylase. This is, at
first sight, counterintuitive because of JMJD2D’s function as a p53
coactivator, as this tumor suppressor normally reduces cell
proliferation, in part by upregulating the p21 cell cycle inhibitor
[57]. However, JMJD2D may primarily stimulate cell proliferation
through to-be-deciphered pathways, whereas JMJD2D’s ability to
coactivate p53 dampens this pro-proliferative function (Fig. 6C). If
so, one would predict that JMJD2D has a greater impact on cell
proliferation in p53-negative cells, and indeed we observed that
JMJD2D depletion in p53
2/2 HCT116 cells resulted in a greater
decrease of cell proliferation compared to wild-type HCT116 cells.
In addition, JMJD2D depletion led to more sub-G1 cells, which
is indicative of apoptosis. This is suggestive of JMJD2D being
a pro-survival molecule. Again, this is somewhat counterintuitive
with JMJD2D being a p53 coactivator, since p53 upregulates pro-
apoptotic genes such as Puma [51]. But again, one can invoke that
JMJD2D primarily stimulates cell survival via pathways not
involving p53, whereas its action through p53 may stifle this pro-
survival activity. If so, JMJD2D’s effect on survival should be
greater in the absence of p53. And in fact, downregulation of
JMJD2D resulted in more sub-G1 cells in p53
2/2 HCT116 cells
compared to corresponding wild-type cells.
The ability of JMJD2D to stimulate cell proliferation and
survival would be consistent with a pro-oncogenic role of
JMJD2D. In this regard, JMJD2D resembles JMJD2A that
likewise appears be required for maximal HCT116 cell growth
[43]. Notably, several reports suggest that JMJD2 genes might be
overexpressed in various cancers. For instance, JMJD2C gene
amplification has been observed in esophageal squamous cell
carcinomas, lung sarcomatoid carcinoma, medulloblastomas and
breast tumors [58–62]. Further, JMJD2B or JMJD2C mRNA are
overexpressed in medulloblastomas, JMJD2A-C mRNA upregula-
tion was noted in prostate tumors and JMJD2B/C mRNA levels
are also enhanced in many breast tumors [8,61–63]. More
importantly, JMJD2B or JMJD2C overexpression induced trans-
formed phenotypes in non-cancerous breast cells, whereas their
downregulation in breast cancer cells inhibited cell proliferation in
vitro or tumorigenesis in xenograft mouse models [62–65].
Collectively, these data suggest that JMJD2 proteins might be
proto-oncoproteins, yet it remains to be studied whether this holds
true for JMJD2D. If so, JMJD2D might be a valid target for cancer
therapy like other JMJD proteins [66]. Interestingly, compounds
related to 2-oxoglutarate, which is a cofactor of JMJD demethy-
lases, and succinate, which is generated from 2-oxoglutarate as
a by-product, have been shown to inhibit JMJD2D catalytic
activity [67,68] and could therefore form a starting point in the
development of small molecule drugs.
In conclusion, our study provides evidence that JMJD2D may
modulate the transcriptional activity of p53, which is one of the
most important tumor suppressors and found mutated in half of all
human tumors [69]. In addition, we provide evidence that
JMJD2D is a pro-proliferative and pro-survival molecule, which
suggests that small molecules targeting JMJD2D could be
beneficial in the treatment of cancer.
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